Companies /Healthcare

Sarepta Therapeutics Inc

NASDAQ: SRPT Biotechnology
$14.53
▼ $0.24 (−1.62%) today
Markets closed · 10:42pm ET

24/7 Wall St. View

SRPT at a Glance

Valuation
Market cap
$1.6B
P/E ratio
740.5
Profitability
Revenue (TTM)
$2.0B
Profit margin
-5.9%
EPS (TTM)
$0.02
Price
52-week range
$15 – $25
24/7 target
$22.78
Street target
$21.77

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: SRPT sarepta.com

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage precision genetic medicine company focused on rare diseases, with its main commercial presence in Duchenne muscular dystrophy (DMD).

Its revenue comes from two product franchises:
- PMO exon-skipping therapies built on its proprietary phosphorodiamidate morpholino oligomer chemistry: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen) and AMONDYS 45 (casimersen). Each is approved under accelerated approval for DMD patients with amenable mutations.
- ELEVIDYS (delandistrogene moxeparvovec-rokl), a single-dose AAV gene therapy now indicated only for ambulatory DMD patients aged 4 and older, and carrying a boxed warning for acute serious liver injury and acute liver failure.

Sarepta also earns collaboration and contract manufacturing revenue from Roche, which commercializes ELEVIDYS outside the U.S., including in Japan.

Following a July 2025 restructuring and pipeline reprioritization, R&D centers on siRNA programs licensed from Arrowhead. These include SRP-1003 for myotonic dystrophy type 1 (DM1) and SRP-1001 for facioscapulohumeral muscular dystrophy (FSHD), both being prepared for Phase 3. The broader portfolio spans muscle, central nervous system and cardiac diseases.

The company is led by CEO Michael Severino, M.D. Updated

Latest Activity

SRPTSarepta Therapeutics
Q3 2026
EPS
$0.13
est $0.36-63.6%
Revenue
$381M
est $350M+8.9%

A $62 million Catalent take-or-pay charge separates a revenue beat from an EPS miss, and management still raised the low end of full-year product revenue guidance to $1.25 billion to $1.3 billion. ELEVIDYS volume shrank under its ambulatory-only label while the PMO exon-skipping franchise carried the quarter. DM1 and FSHD dose data land before year end.

Quarterly EPS — reported vs estimate

SRPT Coverage

Frequently Asked Questions

What does Sarepta Therapeutics do?

Sarepta Therapeutics is a commercial-stage precision genetic medicine company focused on rare diseases, with its main commercial presence in Duchenne muscular dystrophy (DMD).

What is the SRPT stock price target?

24/7 Wall St.'s 12-month price target for SRPT is $22.78, rated Buy. The Wall Street consensus target is $21.77. SRPT price prediction →